Cardiovascular diseases (CVDs) are the leading cause of premature death and disability in
humans and their incidence is on the rise globally. Given their substantial contribution …

Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …

Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …

Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

The scope of this focused update is limited to addressing recommendations on duration of
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …

Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of
thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge …

Background Current guidelines recommend potent platelet inhibition with prasugrel or
ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous …

In 2019, the Japanese Circulation Society published 2 guidelines in the field of coronary
artery disease (CAD):(1) a guideline for acute coronary syndrome (ACS) that integrated …

1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …

Zachęca się pracowników opieki zdrowotnej, aby w pełni uwzględniali te wytyczne
ESC/EACTS, gdy dokonują oceny klinicznej, a także kiedy określają i realizują medyczne …